Table 1 Clinical features and treatment regimens of MRONJ patients

Age

53 (37–71)

54 (29–71)

Gender

 Females/males

31/29 (52/48)

29/31 (48/52)

Ig subtypes

 κ/λ

22/11 (64.9/35.1)

 G/A

23/5 (67.4/16)

 Light chain

5 (16.6)

Stage (Salmon–Durie)

 II/III

10/23 (31/69)

 A/B

27/6 (76/24)

IPI

 I

10 (30.2)

 II/III

9/13 (26.6/43.2)

ECOG

 > 1

4/33 (16.6)

Hemoglobin

 gr/dL

10.7 (6.6–14.7)

Leucocytes

 μL

6100(2760–17,300)

Platelets

 10³/μL

198 (123–337)

C-reactive protein

 mg/dL

6.6 (2.1–215)

LDH

 IU/L

235 (100–556)

β2-microglobulin

 mg/L

4.7 (1.5–47)

Albumin

 g/L

3.6 (2.2–5.1)

Treatment

 VCD, ASCT, LD

60

OS % (5 years)

76

PFS (month)^a

54.3

Follow up duration^a (month)

36 (7.8–99.1)